<DOC>
	<DOCNO>NCT03089086</DOCNO>
	<brief_summary>To estimate effect carriage , approximately 60,000 year 10 , 11 , 12 student offer 4CMenB vaccination South Australia school study period 50 % receive vaccine 2017 50 % 2018 . In year 10 11 student , posterior pharyngeal swab obtain baseline 12 month post baseline estimate difference carriage prevalence serogroups N. meningitidis serogroup B vaccinate unvaccinated participant .</brief_summary>
	<brief_title>South Australian Meningococcal B Vaccine Herd Immunity Study</brief_title>
	<detailed_description>This cluster randomise control study conduct context fund 4CMenB vaccine offer student year 10 , 11 , 12 . Year 10 11 student undergo baseline 12 month posterior pharyngeal swab . Year 12 student undergo baseline posterior pharyngeal swab . Randomisation take place school level stratify school size ( ( &lt; 60 , 60 119 , ≥120 student per year level ) school socio-economic status ( SES ) , measure Index Community Socio-Educational Advantage ( ICSEA ) ; ( ICSEA &lt; 970 , 970 1020 , &gt; 1020 ) For purpose study school define educational institution student year 10 , 11 , 12 physically attend school week . All 260 school metropolitan rural SA approach participate study . All school agree participate randomise 4CMenB vaccine 2017 2018 . Students school randomise receive vaccine baseline receive 4CMenB vaccine 2017 . Students school randomise receive vaccine 12 month posterior pharyngeal swab receive 4CMenB vaccine 2018 . Primary Objectives • Estimate difference serogroups N. meningitidis carriage prevalence follow 12 month pharyngeal swab year 10 11 student receive two dos Bexsero® , compare unvaccinated student . Secondary objective - Estimate difference N. meningitidis serogroup ( A , B , C , W , Y ) carriage prevalence follow 12 month pharyngeal swab year 10 11 student receive two dos Bexsero ® , compare unvaccinated student . - Estimate change serogroups N. meningitidis carriage prevalence 12 month period year 10 11 student receive two dos Bexsero ® , compare unvaccinated student ( baseline vs 12 month swab ) . - Estimate change N. meningitidis serogroup ( A , B , C , W , Y ) carriage prevalence 12 month period student receive two dos Bexsero ® , compare unvaccinated student ( baseline vs 12 month swab ) . - Difference acquisition N. meningitidis serogroup 12 month , define negative baseline positive 12 month N. meningitidis . - Difference persistent carriage N. meningitidis serogroup 12 month , define positive baseline 12 month N. meningitidis . - Difference clearance carriage N. meningitidis serogroup 12 month , define positive baseline negative 12 month N. meningitidis . - Determine difference density measure qPCR N. meningitides ( serogroups ) vaccinate versus unvaccinated student . - Identify characteristic associate carriage prevalence N. meningitidis ( serogroups ) South Australian school student baseline 12 month . - Establish baseline carriage rate N. meningitidis serogroup ( A , B , C , W-135 , Y ) student year 10 , 11 12</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : South Australian secondary school student year 10 , 11 , 12 2017 Written parental consent age 18 Written student consent assent age 18 ( 18 year old old consent ) Available school least first pharyngeal swab willing comply study procedures 1 . Previous anaphylaxis follow component Bexsero vaccine 2 . Previous receipt meningococcal B vaccine ( Bexsero ) 3 . Known pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>meningococcal B vaccine</keyword>
	<keyword>herd immunity</keyword>
	<keyword>adolescent</keyword>
	<keyword>young adult</keyword>
	<keyword>south australia</keyword>
</DOC>